Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or ‘Off-The-Shelf’ Stem Cell Treatment for Heart Attacks

September 5, 2011 By Bio-Medicine.Org

MELBOURNE, Australia, Sept. 5, 2011 /PRNewswire/ — Global
regenerative medicine company, Mesoblast Limited, (ASX: MSB), today
announced that it had received clearance from the European
Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2
clinical trial in Europe for its lead cardiovascular product
Revascor(TM) in conjunction with angioplasty and stent procedures
to prevent heart failure after a major heart attack. Revascor(TM)
is an allogeneic, or “off-the-shelf”, adult stem cell product
derived from Mesoblast’s proprietary Mesenchymal Precursor Cell
(MPC) platform technology which is being developed for use in a
range of cardiovascular diseases including congestive heart
failure, chronic angina, and heart attacks (acute myocardial
infarction).

The placebo-controlled Phase 2 trial, AMICI (Allogeneic
Mesenchymal precursor cell Infusion in myoCardial Infarction), is
approved under Europe’s voluntary harmonization procedure and will
initially recruit patients at multiple European sites, including in
the United Kingdom, The Netherlands and Belgium. Trial recruitment
is subsequently expected to involve sites in additional European
nations, Australia, and the United States. The primary endpoint of
the study will be safety and efficacy at six months in heart attack
patients who will receive either Revascor(TM) at one of two doses
or placebo. Durability of effect will additionally be monitored for
up to 36 months.

Heart attacks remain the biggest killer of people in the
industrialized world. Every year, over 1.7 million people have a
heart attack in Europe, and over 1.1 million in the United States.
Most of these patients undergo an early angioplasty of the blocked
artery accompanied by implantation of a metal stent to keep the
artery open long-term. However, a significant number of the
surviving patients subsequently become disabled with heart
failure.

Revascor(TM) is injected by a simple intracoronary infusion at
the same time as the

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
Biotronik
FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech